Tag: DynamX

Elixir Medical Expands BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System

MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany. The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting […]

Elixir Medical Announces Outstanding 24-month Data for DynamX Coronary Bioadaptor System, Demonstrating Strong Safety With No Target Lesion Revascularization, Myocardial Infarction or Thrombosis Through 24 Months

Successful DynamX Bioadaptor Live Case Presented at Singapore Live MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to […]

Elixir Medical Announces Outstanding 12-Month Data for DynamX Coronary Bioadaptor System, Demonstrating No Target Vessel Revascularization, No Thrombosis and Positive Adaptive Remodeling of the Artery

PARIS–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced outstanding 12-month data for the DynamX™ Coronary Bioadaptor System, the first coronary artery implant that adapts to vessel physiology. Results will be presented live tomorrow at 14:12 CEST on […]

Elixir Medical to Present 9 and 12-Month Clinical and Imaging Data for the DynamX Bioadaptor, Showcasing the Next Frontier Beyond Stenting at EuroPCR 2019

MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it will release at EuroPCR in Paris 9 and 12-month clinical and imaging data for the DynamX™ Novolimus-eluting Bioadaptor System, […]